0001209191-23-025720.txt : 20230426
0001209191-23-025720.hdr.sgml : 20230426
20230426171914
ACCESSION NUMBER: 0001209191-23-025720
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230424
FILED AS OF DATE: 20230426
DATE AS OF CHANGE: 20230426
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DOBMEIER ERIC
CENTRAL INDEX KEY: 0001202785
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37345
FILM NUMBER: 23850859
MAIL ADDRESS:
STREET 1: C/O SAETTLE GENETICS INC
STREET 2: 21823 30TH DRIVE SE
CITY: BOTHELL
STATE: WA
ZIP: 98021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CHINOOK THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001435049
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 206-485-7051
MAIL ADDRESS:
STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900
CITY: SEATTLE
STATE: WA
ZIP: 98109
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH, INC.
DATE OF NAME CHANGE: 20111107
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH
DATE OF NAME CHANGE: 20080514
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-24
0
0001435049
CHINOOK THERAPEUTICS, INC.
KDNY
0001202785
DOBMEIER ERIC
C/O CHINOOK THERAPEUTICS, INC.
400 FAIRVIEW AVE. NO., 9TH FLOOR
SEATTLE
WA
98109
1
1
0
0
President, CEO
0
Common Stock
2023-04-24
4
M
0
25000
0.42
A
326138
D
Common Stock
2023-04-24
4
S
0
23800
21.5768
D
302338
D
Common Stock
2023-04-24
4
S
0
1200
22.2592
A
301138
D
Stock Option (Right to Buy)
0.42
2023-04-24
4
M
0
25000
0.00
D
2030-03-17
Common Stock
25000
313555
D
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated December 22, 2022.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.22 to $22.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.22 to $22.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The stock option vested as to 25% of the total shares monthly on March 6, 2021, and thereafter vests as to 1/48 of the total shares until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
/s/ Kirk Schumacher, Attorney-in-Fact
2023-04-26